X-linked hypophosphatemia and growth
- 872 Downloads
X-Linked hypophosphatemia (XLH) is the most common form of hereditary rickets caused by loss-of function mutations in the PHEX gene. XLH is characterized by hypophosphatemia secondary to renal phosphate wasting, inappropriately low concentrations of 1,25 dihydroxyvitamin D and high circulating levels of fibroblast growth factor 23 (FGF23). Short stature and rachitic osseous lesions are characteristic phenotypic findings of XLH although the severity of these manifestations is highly variable among patients. The degree of growth impairment is not dependent on the magnitude of hypophosphatemia or the extent of legs´ bowing and height is not normalized by chronic administration of phosphate supplements and 1α hydroxyvitamin D derivatives. Treatment with growth hormone accelerates longitudinal growth rate but there is still controversy regarding the potential risk of increasing bone deformities and body disproportion. Treatments aimed at blocking FGF23 action are promising, but information is lacking on the consequences of counteracting FGF23 during the growing period. This review summarizes current knowledge on phosphorus metabolism in XLH, presents updated information on XLH and growth, including the effects of FGF23 on epiphyseal growth plate of the Hyp mouse, an animal model of the disease, and discusses growth hormone and novel FGF23 related therapies.
KeywordsPhosphate Rickets Growth Bone Growth plate Hypophosphatemia
This work was supported by the National Plan I + D + I 2008-2011, Instituto de Salud Carlos III (PI12/00987) and also by the National Plan I + D + I 2013-2016 Instituto de Salud Carlos III (PI14/00702 and PI15/02122), European Regional Development Funds 2013-2016 (ERDF, Grupín 14-020) and by the Foundation of the University of Oviedo (FUO).
Compliance with ethical standards
The article did not involve human or animal participation. Therefore, informed consent or IRB approval were not needed.
Conflict of interest
The authors declare that they have no conflict of interest.
•The manuscript has not been submitted to more than one journal.
•The manuscript has not been published previously.
•No data/figures have been fabricated or manipulated.
•A single study is not split up into several parts.
•No data, text or theories are being plagiarized.
•All authors have been informed about the submission of the paper and all have contributed to the article.
- 5.Villa-Bellosta R, Ravera S, Sorribas V, Stange G, Levi M, Murer H, Biber J, Forster IC. The Na + −pi cotransporter PiT-2 (SLC20A2) is expressed in the apical membrane of rat renal proximal tubules and regulated by dietary pi. American Journal of Physiology. Renal Physiology. 2009;296:691–9.CrossRefGoogle Scholar
- 10.Ubaidus S, Li M, Sultana S, de Freitas PHL, Oda K, Maeda T, Takagi R, Amizuka N. FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling. Journal of Electron Microscopy. 2009;58:381–92.CrossRefPubMedGoogle Scholar
- 12.Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Jüppner H, Jonsson KB. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004;145:3087–94.CrossRefPubMedGoogle Scholar
- 15.Toro CL. Rol de Klotho y FGF23 en la regulación de fosfato y calcio plasmático. Rev Hosp Clin Univ Chile. 2010;23:25–32.Google Scholar
- 18.Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Review of Development Biology. 2015;4:215–66.Google Scholar
- 21.Webster R, Sheriff S, Faroqui R, Siddiqui F, Hawse JR, Amlal H. Klotho/fibroblast growth factor 23- and PTH-independent estrogen receptor-alpha-mediated direct downregulation of NaPi-IIa by estrogen in the mouse kidney. American Journal of Physiology. Renal Physiology. 2016;311:F249–59.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Imura A, Tsuji Y, Murata M, Maeda R, Kubota K, Iwano A, Obuse C, Togashi K, Tominaga M, Kita N, Tomiyama K, Iijima J, Nabeshima Y, Fujioka M, Asato R, Tanaka S, Kojima K, Ito J, Nozaki K, Hashimoto N, Ito T, Nishio T, Uchiyama T, Fujimori T, Nabeshima Y. Alpha-klotho as a regulator of calcium homeostasis. Science. 2007;316:1615–8.CrossRefPubMedGoogle Scholar
- 27.Ramussen H, Anast C. Familial hypophosphatemic rickets and vitamin D-dependent rickets. In: Wyngaarden JB, Fredericson DS, Goldstain JL, Brrown MS, editors. The Metabolic Basis of Inherit Disease. N Y: McGraw-Hill; 1983. p. 1743–73.Google Scholar
- 28.Collins JF, Bulus N, Ghishan FK. Sodium-phosphate transporter adaptation to dietary phosphate deprivation in normal and hypophosphatemic mice. American Journal of Physics. 1995;268:917–24.Google Scholar
- 31.Tenenhouse H. X-linked hypophosphataemia: a homologous disorder in humans and mice. Nephrology, Dialysis, Transplantation. 1999;333–41Google Scholar
- 35.Dixon PH, Christie PT, Wooding C, Trump D, Grieff M, Holm I, Gertner JM, Schmidtke J, Shah B, Shaw N, Smith C, Tau C, Schlessinger D, Whyte MP, Thakker RV. Mutational analysis of PHEX Gene in X-liked hypophosphatemia. The Journal of Clinical Endocrinology and Metabolism. 2014;83:3615–23.Google Scholar
- 36.Beck L, Soumounou Y, Martel J, Krishnamurthy G, Gauthier C, Goodyer CG, Tenenhouse HS. Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypophosphatemic mice. The Journal of Clinical Investigation. 1997;99:1200.CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. The Journal of Clinical Endocrinology and Metabolism. 2002;87:4957–60.CrossRefPubMedGoogle Scholar
- 50.Živičnjak M, Schnabel D, Billing H, Staude H, Filler G, Querfeld U, Schumacher M, Pyper A, Schröder C, Brämswig J, Haffner D. Hypophosphatemic Rickets Study Group of Arbeitsgemeinschaft für Pädiatrische Endokrinologie and Gesellschaft für Pädiatrische Nephrologie. Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatric Nephrology. 2011;26:223–31.CrossRefPubMedGoogle Scholar
- 52.Jehan F, Gaucher C, Nguyen TM, Walrant-Debray O, Lahlou N, Sinding C, Déchaux M, Garabédian M. Vitamin D receptor genotype in hypophosphatemic rickets as a predictor of growth and response to treatment. The Journal of Clinical Endocrinology and Metabolism. 2008;93:4672–82.CrossRefPubMedGoogle Scholar
- 66.Ovejero D, Lim YH, Boyce AM, Gafni RI, McCarthy E, Nguyen TA, Eichenfield LF, DeKlotz CM, Guthrie LC, Tosi LL, Thornton PS, Choate KA, Collins MT. Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment. Osteoporosis International. 2016;27:3615–26.CrossRefPubMedGoogle Scholar
- 69.Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. The Journal of Clinical Endocrinology and Metabolism. 2010;95:1846–50.CrossRefPubMedPubMedCentralGoogle Scholar
- 71.Wilson DM, Lee PD, Morris AH, Reiter EO, Gertner JM, Marcus R, Valerie E. Ron G. Growth hormone therapy in hypophosphatemic rickets. American Journal of Diseases of Children (1911). 1991;145:1165–70.Google Scholar
- 75.Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:6500–5.CrossRefPubMedPubMedCentralGoogle Scholar
- 77.Wöhrle S, Bonny O, Beluch N, Gaulis S, Stamm C, Scheibler M, Müller M, Kinzel B, Thuery A, Brueggen J, Hynes NE, Sellers WR, Hofmann F, Graus-Porta D. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. Journal of Bone and Mineral Research. 2011;26:2486–97.CrossRefPubMedGoogle Scholar
- 80.Wöhrle S, Henninger C, Bonny O, Thuery A, Beluch N, Hynes NE, Guagnano V, Sellers WR, Hofmann F, Kneissel M, Graus PD. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. Journal of Bone and Mineral Research. 2013;28:899–911.CrossRefPubMedGoogle Scholar
- 85.Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO. Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. The Journal of Clinical Endocrinology and Metabolism. 2015;100:2565–73.CrossRefPubMedPubMedCentralGoogle Scholar
- 86.Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna KL, Peacock M. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. The Journal of Clinical Investigation. 2014;124:1587–97.CrossRefPubMedPubMedCentralGoogle Scholar